CLS presents imILT® and poster at Porto Precision Oncology Meeting in Portugal

Clinical Laserthermia Systems (CLS) (publ) has been invited to present imILT® at the 2nd Porto Precision Oncology Meeting on 19 May in Portugal. At the meeting, which has its focus on treatment of pancreatic cancer, CLS will also present a poster describing an imILT® treatment performed by professor Belarmino Gonçalves, at Portoguese Institut of Oncology in Porto.

At the Porto Precision Oncology Meeting new methods for treating pancreatic cancer will be discussed. It is an excellent opportunity for us to present imILT® and our poster in front of an audience of doctors and researchers, in the field of immuno-oncology, said Lars-Erik Eriksson, CEO of CLS.

CLS develops and markets the TRANBERG®|Thermal Therapy System, as well as disposable materials and methods for heat-induced immunotherapy for safe and gentle treatment of cancerous tumors. Professor Belarmino Gonçalves, at Portoguese Institut of Oncology in Porto, is leading a clinical study of imILT® treatment of pancreatic cancer, conducted by CLS as a Horizon2020 project. One patient has been treated outside the study, and in cooperation with professor Gonçalves CLS is presenting a poster describing the patient, the procedure and treatment follow up. The poster will be presented at the 2nd Porto Precision Oncology Meeting and commented upon by a doctor from professor Gonçalves’ team. In conjunction with the meeting the poster will be published on the CLS web page.

2nd Porto Precision Oncology Meeting  takes place on the 19 May at Instituto de Patologia e Imunologia Molecular da Universidade do Porto in Portugal. More about the meeting.

This information is such that Clinical Laserthermia Systems AB (publ) is required to publish pursuant to the EE Market Abuse Directive. The contact person arranged for the release of this information on 12 April 2017.

Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00   E-mail:

Clinical Laserthermia Systems AB (publ) develops and markets a safe, gentle, effective, and clinically documented therapy for treatment of solid cancer tumors. The product is based on immunostimulating interstitial laser thermotherapy (imILT). CLS is listed on Nasdaq First North under the stock symbol CLS B. Certified Adviser is Västra Hamnen Corporate Finance. More information is available on the Company's website


Documents & Links